Supplementary Online Content


eTable. SPRINT Major Inclusion and Exclusion Criteria

eFigure 1. Algorithm Used to Define the Study Cohort Using Inclusion and Exclusion Criteria for CKD Patients in the SPRINT Trial, Except Amount of Proteinuria

eFigure 2. Kaplan-Meier Survival Curves of Patients With Follow-up SBP <120 vs. 120-139 mmHg in a Propensity Score-Matched Cohort of 5,000 Patients Defined Using Inclusion and Exclusion Criteria for CKD Patients in the SPRINT Trial, Except Amount of Proteinuria

This supplementary material has been provided by the authors to give readers additional information about their work.
eTable. SPRINT Major Inclusion and Exclusion Criteria

Inclusion criteria:

Greater than or equal to 50 years of age

Systolic blood pressure:

- 130 – 180 mm Hg on 0 or 1 medication
- 130 – 170 mm Hg on up to 2 medications
- 130-160 mm Hg on up to 3 medications
- 130-150 mm Hg on up to 4 medications

Risk (one or more of the following):

- Presence of clinical or subclinical cerebrovascular disease (not stroke)
- Chronic kidney disease, defined as eGFR 20-59 ml/min/1.73m2
- Framingham Risk Score for 10-year CVD risk \(\geq\) 15%

Not needed if eligible based on preexisting CVD or CKD

Age \(\geq\) 75 years of age.

Exclusion Criteria

Stroke

Diabetes

Congestive heart failure (symptoms or EF <35%)

Proteinuria >1 g/d

CKD with eGFR < 20 ml/min/1.73m2 (MDRD)

Concerns regarding adherence
**eFigure 1.** Algorithm Used to Define the Study Cohort Using Inclusion and Exclusion Criteria for CKD Patients in the SPRINT Trial, Except Amount of Proteinuria

- 651,749 patients with non-dialysis dependent CKD and available BP measurement
- 145,530 patients eligible based on SPRINT inclusion/exclusion criteria
- 506,219 patients not eligible
- 51,209 patients had unchanged or increased SBP during follow-up
- 7,742 patients had SBP<120 mmHg at >50% of follow-up visits
- 86,579 patients had SBP 120-139 mmHg at >50% of follow-up visits
- Number of BP meds during follow-up
- 2,500 patients had SBP<120 mmHg and increased number of BP meds during follow-up
- 34,858 patients had SBP 120-130 mmHg and increased number of BP meds during follow-up
- Propensity score-matching
- 2,500 patients with SBP<120 mmHg and increased number of BP meds during follow-up
- 2,500 patients with SBP 120-<140 mmHg and increased number of BP meds during follow-up
- 56,963 patients had unchanged or decreased number of BP medications during follow-up
**eFigure 2.** Kaplan-Meier Survival Curves of Patients With Follow-up SBP <120 vs. 120-139 mmHg in a Propensity Score-Matched Cohort of 5,000 Patients Defined Using Inclusion and Exclusion Criteria for CKD Patients in the SPRINT Trial, Except Amount of Proteinuria